StockNews.AI
PALI
StockNews.AI
180 days

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

1. Palisade Bio secures CAD$1.39M non-dilutive SR&ED funding for preclinical costs. Funding supports joint development with Giiant Pharma. 2. The funding boosts progress on PALI-2108’s clinical development. Early stage studies continue under a co-development plan. 3. Phase 1a/b study in UC patients and healthy volunteers is underway. Topline data expected in H1 2025, signaling key milestone. 4. Non-dilutive funding reduces cash burn and supports clinical ramp-up. This milestone enhances confidence in PALI-2108's prospects.

7m saved
Insight
Article

FAQ

Why Bullish?

The non-dilutive funding reduces cash burn and validates the PALI-2108 approach. Similar biotech advancements have historically led to modest price gains when clinical milestones are met, though early-stage risks remain.

How important is it?

The infusion of non-dilutive funding and key trial updates are significant catalysts for PALI’s pipeline. However, early-stage clinical risks and milestone uncertainties moderate its overall short-term impact.

Why Long Term?

Phase 1a/b trial results and subsequent clinical milestones are long-term catalysts. Successful progression can significantly boost investor sentiment and valuation over time.

Related Companies

Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108 Ongoing progress of Palisade Bio’s Phase 1a/b UC study of PALI-2108 with topline data expected in the first half of 2025 Carlsbad, CA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the receipt of CAD$1.39 million Canadian SR&ED credits for reimbursement of prior pre-clinical costs for PALI-2108 incurred under the company’s joint development plan with Giiant. “This non-dilutive funding, which resulted from our pre-clinical studies previously conducted in Montreal under our co-development agreement with Giiant, bolsters our efforts to potentially bring a solution to patients,” said JD Finley, Chief Executive Officer of Palisade Bio, “We are pleased with the continued progress made with our PALI-2108 program and look forward to reporting topline data in the first half of 2025 from our ongoing Phase 1a/b study.” The Company is currently conducting a Phase 1a/b single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, alongside an open-label study involving a patient cohort with UC. For more information about the Phase 1a/b clinical study, visit clinicaltrials.gov and reference identifier NCT06663605. About Palisade Bio  Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com. Forward Looking Statements Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the SAD portion of the Company’s Phase 1b/2a clinical study, indications and anticipated benefits of PALI-2108 and the expected timing of the release of topline data from the Phase 1b/2a clinical study. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company is heavily dependent on the success of PALI-2108, which is in the early stages of clinical development and may not successfully progress through clinical development or receive regulatory approval; preliminary clinical study results or the results from earlier preclinical studies may not be predictive of final or future results and unexpected adverse side effects or inadequate efficacy of PALI-2108 may limit its development, regulatory approval and/or commercialization; the Company needs to raise significant additional funds to support its operations and the continued development of PALI-2108; the timing and outcome of the Company’s current and anticipated clinical studies related to its product candidates; indications of use and estimates about the size and growth potential of the markets for the Company’s product candidates, and its ability to serve those markets, including any potential revenue generated; the Company’s ability to maintain the Nasdaq listing of its securities; the Company’s ability to compete effectively in a competitive industry; the Company’s ability to identify and qualify manufacturers to provide API and manufacture drug product; the Company’s ability to enter into commercial supply agreements; the Company’s ability to attract and retain key scientific or management personnel; the accuracy of the Company’s estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and the impact of any global event on the Company’s business, and operations, and supply. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations ContactJTC Team, LLCJenene Thomas 908-824-0775PALI@jtcir.com

Related News